Abstract
Background: Worldwide, at least 2.8 million people die each year as a result of being overweight or obese. Obesity leads to metabolic syndrome, a pathological condition characterized by adverse metabolic effects on blood pressure, cholesterol, triglycerides and insulin resistance. Population- based investigations have suggested that obesity and metabolic syndrome may be associated with poorer cognitive performance.
Method: A structured search of bibliographic source (PubMed) was undertaken. The following terms “inflammation and obesity and brain”, “cholinergic system and obesity”, “cholinergic system and metabolic syndrome”, “Cognitive impairment and obesity” and “metabolic syndrome and brain” were used as search strings. Results: Over 200 papers, mainly published in the past 10 years were analysed. The major results regarded keyword “metabolic syndrome and brain” followed by, “Cognitive impairment and obesity”, “inflammation and obesity and brain”, “cholinergic system and obesity” and “cholinergic system and metabolic syndrome”. Most papers were pre-clinical but, in general, they were inhomogeneous. Therefore, the results were cited according their contribution to clarify the molecular involvement of obesity and/or metabolic syndrome in cholinergic impairment. Conclusion: This review focuses on the correlation between brain cholinergic system alterations and high-fat diet, describing the involvement of cholinergic system in inflammatory processes related to metabolic syndrome and obesity, which may lead to cognitive decline. Metabolic syndrome has been suggested as a risk factor for cerebrovascular diseases and has been associated with cognitive impairment in different functional brain domains. Preclinical and clinical studies have identified the cholinergic system as a specific target of metabolic syndrome and obesity. The modifications of cholinergic neurotransmission and its involvement in neuro-inflammation may be related to cognitive impairment that affects obese patients.Keywords: Brain, cholinergic system, cognitive decline, inflammation, metabolic syndrome, obesity.
CNS & Neurological Disorders - Drug Targets
Title:Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
Volume: 16 Issue: 6
Author(s): Ilenia Martinelli , Daniele Tomassoni , Michele Moruzzi , Enea Traini , Francesco Amenta and Seyed Khosrow Tayebati*
Affiliation:
- School of Medicinal Sciences and Health Products, University of Camerrino, Via Madonna delle Carceri, 9, 62032 Camerino (MC),Italy
Keywords: Brain, cholinergic system, cognitive decline, inflammation, metabolic syndrome, obesity.
Abstract: Background: Worldwide, at least 2.8 million people die each year as a result of being overweight or obese. Obesity leads to metabolic syndrome, a pathological condition characterized by adverse metabolic effects on blood pressure, cholesterol, triglycerides and insulin resistance. Population- based investigations have suggested that obesity and metabolic syndrome may be associated with poorer cognitive performance.
Method: A structured search of bibliographic source (PubMed) was undertaken. The following terms “inflammation and obesity and brain”, “cholinergic system and obesity”, “cholinergic system and metabolic syndrome”, “Cognitive impairment and obesity” and “metabolic syndrome and brain” were used as search strings. Results: Over 200 papers, mainly published in the past 10 years were analysed. The major results regarded keyword “metabolic syndrome and brain” followed by, “Cognitive impairment and obesity”, “inflammation and obesity and brain”, “cholinergic system and obesity” and “cholinergic system and metabolic syndrome”. Most papers were pre-clinical but, in general, they were inhomogeneous. Therefore, the results were cited according their contribution to clarify the molecular involvement of obesity and/or metabolic syndrome in cholinergic impairment. Conclusion: This review focuses on the correlation between brain cholinergic system alterations and high-fat diet, describing the involvement of cholinergic system in inflammatory processes related to metabolic syndrome and obesity, which may lead to cognitive decline. Metabolic syndrome has been suggested as a risk factor for cerebrovascular diseases and has been associated with cognitive impairment in different functional brain domains. Preclinical and clinical studies have identified the cholinergic system as a specific target of metabolic syndrome and obesity. The modifications of cholinergic neurotransmission and its involvement in neuro-inflammation may be related to cognitive impairment that affects obese patients.Export Options
About this article
Cite this article as:
Martinelli Ilenia , Tomassoni Daniele , Moruzzi Michele , Traini Enea , Amenta Francesco and Tayebati Khosrow Seyed *, Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions, CNS & Neurological Disorders - Drug Targets 2017; 16 (6) . https://dx.doi.org/10.2174/1871527316666170428123853
DOI https://dx.doi.org/10.2174/1871527316666170428123853 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atherosclerosis, Degenerative Aortic Stenosis and Statins
Current Drug Targets Helicobacter pylori: An Overview on Antimicrobials and Drug Delivery Systems for its Eradication
Current Drug Delivery Caffeoylquinic Acids with Potential Biological Activity from Plant In vitro Cultures as Alternative Sources of Valuable Natural Products
Current Pharmaceutical Design Editorial [Hot topic: Interstitial Lung Disease with Connective Tissue Diseases (Guest Editor: Eric Matteson)]
Current Rheumatology Reviews Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Left Ventricular Hypertrophy: A Shift in Paradigm
Current Medicinal Chemistry Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?
Current Vascular Pharmacology CD38 in Chronic Lymphocytic Leukemia: From Bench to Bedside?
Mini-Reviews in Medicinal Chemistry Molecular Mechanism of Aggravation of Hypertensive Organ Damages by Short-Term Blood Pressure Variability
Current Hypertension Reviews Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology Synthesis and Anti-tubercular Activity of 6-(<i>4</i>-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2<i>H</i>)-one Derivatives Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review
Current Vascular Pharmacology The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Recent Approaches for Angiogenesis in Search of Successful Tissue Engineering and Regeneration
Current Stem Cell Research & Therapy Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry